INC280

Study of EGF816 in Combination With Selected Targeted Agents in EGFR-mutant NSCLC

Study Efficacy and Safety of INC280 in Patients With Advanced Hepatocellular Carcinoma.

Study of Efficacy and Safety of Novel Spartalizumab Combinations in Patients With Previously Treated Unresectable or Metastatic Melanoma

LGX818 and MEK162 in Combination With a Third Agent (BKM120, LEE011, BGJ398 or INC280) in Advanced BRAF Melanoma

INC280 Combined With Bevacizumab in Patients With Glioblastoma Multiforme

A Phase 2 Study of the MET Kinase Inhibitor INC280 in Papillary Renal Cell Cancer

Study of Efficacy and Safety of Nivolumab in Combination With EGF816 and of Nivolumab in Combination With INC280 in Patients With Previously Treated Non-small Cell Lung Cancer

INC280 and Erlotinib Hydrochloride in Treating Patients With Non-small Cell Lung Cancer

A Safety and Efficacy Study of INC280 and Gefitinib in Patients With EGFR Mutated, c-MET-amplified NSCLC Who Have Progressed After EGFRi Treatment

Study of INC280 in Patients With c-MET Dependent Advanced Solid Tumors

A Dose Escalation Study to Assess PK, Safety and Tolerability of INC280 When Taken With Food in cMET Dysregulated Advanced Solid Tumors.

A Phase I Study of INC280 in Japanese Patients With Advanced Solid Tumors

A Phase II, Open Label, Multiple Arm Study of AUY922, BYL719, INC280, LDK378 and MEK162 in Chinese Patients With Advanced Non-small Cell Lung Cancer

INC280 in Healthy Subjects With Impaired Hepatic Function and Subjects With Normal Hepatic Function

A DDI Study to Assess the Effect of INC280 on the PK of Midazolam and Caffeine in Patients With cMET-dysregulated Advanced Solid Tumors

A Drug-drug Interaction (DDI) Study to Assess the Effect of INC280 on the Pharmacokinetics of Digoxin and Rosuvastatin in Patients With cMET-dysregulated Advanced Solid Tumors

Study of Safety and Efficacy of INC280 and Cetuximab, in Adult c-MET Positive mCRC and HNSCC Patients After Progression on Cetuximab or Panitumumab Therapy

Study of Oral cMET Inhibitor INC280 in Chinese Patients With EGFR Wild-type Advanced Non-small Cell Lung Cancer (NSCLC)

Safety and Efficacy of INC280 and Buparlisib (BKM120) in Patients With Recurrent Glioblastoma

Study of Efficacy and Safety INC280 in Patients With Advanced Hepatocellular Carcinoma